Financial reports
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Apr 24
8-K
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
14 Mar 24
8-K
Departure of Directors or Certain Officers
7 Feb 24
8-K
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
12 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Nov 23
8-K
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
13 Nov 23
8-K
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
5 Sep 23
8-K
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
14 Aug 23
8-K
Other Events
10 Jul 23
8-K
Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
5 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
22 Aug 23
424B4
Prospectus supplement with pricing info
30 Jun 23
S-1MEF
Registration of additional securities for an S-1
29 Jun 23
S-1/A
IPO registration (amended)
29 Jun 23
FWP
Free writing prospectus
23 Jun 23
S-1/A
IPO registration (amended)
23 Jun 23
S-1/A
IPO registration (amended)
9 Jun 23
FWP
Free writing prospectus
31 May 23
S-1/A
IPO registration (amended)
18 May 23
FWP
Free writing prospectus
13 Feb 23
Proxies
No filings
Other
CERT
Certification of approval for exchange listing
30 Jun 23
EFFECT
Notice of effectiveness
30 Jun 23
SEC STAFF
SEC staff action: Order
29 Jun 23
CORRESP
Correspondence with SEC
27 Jun 23
CORRESP
Correspondence with SEC
27 Jun 23
CORRESP
Correspondence with SEC
9 Jun 23
UPLOAD
Letter from SEC
7 Jun 23
CORRESP
Correspondence with SEC
14 Feb 23
CORRESP
Correspondence with SEC
14 Feb 23
CORRESP
Correspondence with SEC
9 Feb 23